PTC Therapeutics Inc. (PTCT)

25.01
NASDAQ : Health Technology
Prev Close 25.01
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.12 / 28.75
Avg Volume 847.00K
Exchange NASDAQ
Shares Outstanding 41.49M
Market Cap 992.86M
EPS -4.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.

Notable Monday Option Activity: PTCT, OLN, ICPT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PTC Therapeutics Inc , where a total of 3,147 contracts have traded so far, representing approximately 314,700 underlying shares. That amounts to about 46.8% of PTCT's average daily trading volume over the past month of 672,560 shares.

Notable Monday Option Activity: PTCT, DG, IDCC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 6,631 contracts has been traded thus far today, a contract volume which is representative of approximately 663,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 75.2% of PTCT's average daily trading volume over the past month, of 882,305 shares.

Short Interest Increases 19% For PTCT

The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 1,353,958 share increase in total short interest for PTC Therapeutics Inc , to 8,436,994, an increase of 19.12% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Spinal Muscular Atrophy Program Advances Into Pivotal Study In SMA Patients

Spinal Muscular Atrophy Program Advances Into Pivotal Study In SMA Patients

- Concluded dose-finding part of SUNFISH study -

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

RG7916 Increased SMN Protein Production In SUNFISH Clinical Trial In Patients With Type 2/3 Spinal Muscular Atrophy

RG7916 Increased SMN Protein Production In SUNFISH Clinical Trial In Patients With Type 2/3 Spinal Muscular Atrophy

- Data presented at the 22nd International World Muscle Society (WMS) Congress -

Noteworthy Wednesday Option Activity: PTCT, SNX, UPL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 4,409 contracts has been traded thus far today, a contract volume which is representative of approximately 440,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 69.6% of PTCT's average daily trading volume over the past month, of 633,365 shares.

PTC Therapeutics Announces Winners Of Global Duchenne Muscular Dystrophy Patient Group STRIVE Awards In Recognition Of World Duchenne Awareness Day

PTC Therapeutics Announces Winners Of Global Duchenne Muscular Dystrophy Patient Group STRIVE Awards In Recognition Of World Duchenne Awareness Day

- Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

Jim Cramer says some sellers are making a big mistake by not giving top-notch CEOs the benefit of the doubt despite earnings upheaval.

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Jim Cramer is bullish on Hertz Global Holdings, Honeywell, PetMed Express, and Allergan.

TheStreet Quant Rating: D (Sell)